INVEGA SUSTENNA® is the commercial brand name of Paliperidone Palmitate Injection (3‑Month), a long‑acting injectable atypical antipsychotic developed by Janssen. After intramuscular injection, it slowly releases paliperidone, which blocks central dopamine D2 and serotonin 5‑HT2A receptors to exert antipsychotic effects.…
Datroway® is the commercial brand name of Datopotamab Deruxtecan for Injection (Chinese brand name: Dazhuoyou / 达卓优 ®), a TROP2-targeted antibody-drug conjugate (ADC) co-developed by Daiichi Sankyo and AstraZeneca. Constructed with Daiichi Sankyo’s proprietary DXd ADC platform, it consists of…
Enstilar® is the commercial brand name of Calcipotriol and Betamethasone Dipropionate Foam (Chinese brand name: Enshida / 恩适达 ®), a compound topical foam preparation developed by LEO Pharma. Calcipotriol modulates keratinocyte proliferation and differentiation, while betamethasone dipropionate delivers potent anti-inflammatory,…
Rystiggo® is the commercial brand name of Rozanolixizumab Injection, a humanized anti-FcRn monoclonal antibody developed by UCB Pharma. It binds to the neonatal Fc receptor (FcRn), accelerates the clearance of pathogenic immunoglobulin G (IgG) autoantibodies in the body, reduces circulating…
Ruinier® is the commercial brand name of Treprostinil Injection, a synthetic prostacyclin analog developed by Zhaoke Pharmaceutical. It activates prostacyclin receptors to induce pulmonary and systemic vasodilation, inhibit platelet aggregation, reverse vascular remodeling, reduce pulmonary artery pressure and right heart…
Tibsovo® is the commercial brand name of Ivosidenib Tablets, an oral selective mutant IDH1 inhibitor co-developed by CStone Pharmaceuticals and Servier. It selectively inhibits mutated isocitrate dehydrogenase 1 (IDH1) enzyme, reduces abnormal oncometabolite 2-hydroxyglutarate production, restores normal cellular differentiation of…
Fareston® is the commercial brand name of Toremifene Citrate Tablets, a selective estrogen receptor modulator (SERM) developed by Orion Corporation. It competitively binds to estrogen receptors on breast cancer cells, blocks estrogen-mediated tumor cell proliferation, and exerts anti-tumor endocrine therapeutic…
Fampyra® is the commercial brand name of Fampridine Sustained-release Tablets, a sustained-release oral potassium channel blocker developed by Biogen. It blocks voltage-gated potassium channels on demyelinated nerve axons, enhances nerve conduction velocity in damaged central nervous system nerve fibers, improves…
Qarziba® is the commercial brand name of Dinutuximab beta Injection, a chimeric monoclonal antibody targeting GD2 ganglioside developed by EUSA Pharma. It binds to the GD2 antigen expressed on the surface of neuroblastoma tumor cells, mediates antibody-dependent cellular cytotoxicity (ADCC)…
Jiatailai® is the commercial brand name of Sacituzumab Tirumotecan for Injection, a Trop-2 targeted antibody-drug conjugate (ADC) independently developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. It specifically binds to Trop-2 antigen highly overexpressed on solid tumor cell membrane via humanized…